Technion Biologist David Meiri Brings Cannabis Therapies to Patients via Teva Deal
Israeli researcher David Meiri's cannabis extract library is set for a Teva partnership to treat epilepsy, endometriosis and bowel disease.
David Meiri, head of cancer biology and cannabinoid research at the Technion's Faculty of Biology in Haifa, is finalizing a deal with Israeli pharmaceutical company Teva to market a line of cannabis extracts called Evidence Base. Meiri says clinical trials have shown the extracts can help treat epilepsy, endometriosis, and inflammatory bowel syndrome. Because the product is an extract rather than a single purified molecule, it has not yet gone through Israel's Ministry of Health drug approval process, which Meiri says can take seven years and cost $500 million for a molecule-specific treatment.
Meiri's lab has spent years building what he describes as an unmatched library of cannabis molecules, becoming the first in the world to classify ten separate families of the plant's active compounds. That work has made his lab a go-to resource for growers, startups, and scientists studying cannabis. He is also investigating how specific cannabis strains killed cancer cells in mice with leukemia, and is now trying to pinpoint which of roughly 400 active compounds in the extract are responsible for the anticancer effect.
Meiri's research extends beyond cannabis. Using similar molecular analysis, he has found that a particular type of psilocybin mushroom may reduce the buildup of brain plaque associated with Alzheimer's disease. He was also recruited by Israel's Ministry of Health to help treat young survivors of the 2023 Nova festival attack, applying his knowledge of how different psychedelic substances affect the brain to tailor treatment depending on what each survivor had taken during the attack.
Meiri's interest in plants began on a cooperative farm, where he took over agricultural work after his father suffered a stroke. He went on to study biology, biochemistry, and plant molecular biology, led Tel Aviv University's Botanic Gardens, and conducted cancer research in Toronto before returning to Israel to run a lab at the Technion's Integrated Cancer Centre.
“We were the first lab in the world that succeeded in analysing ten different families of these molecules.”
If approved, Meiri's cannabis extracts could give patients with epilepsy, endometriosis, and inflammatory bowel disease access to treatments backed by clinical research and a major pharmaceutical company. His broader molecule library and findings on cancer, Alzheimer's-linked plaque, and psychedelic-based trauma treatment could inform further research that benefits patients well beyond Israel.
Sources
- The Israeli biologist using cannabis to fight IBS, epilepsy – and cancer - The Jewish ChronicleThe Jewish Chronicle, November 16, 2026
- The Israeli biologist using cannabis to fight IBS, epilepsy – and cancer - Iraneuropesays.com, November 16, 2026
Summarised in our own words from the reporting above.
Tikkun olam, today. This is part of tikkun olam, the Jewish idea of repairing the world, and every one of us can add to it.